Cargando…
Therapeutic Drug Monitoring of Tyrosine Kinase Inhibitors Using Dried Blood Microsamples
Therapeutic drug monitoring (TDM) of tyrosine kinase inhibitors (TKIs) is not yet performed routinely in the standard care of oncology patients, although it offers a high potential to improve treatment outcome and minimize toxicity. TKIs are perfect candidates for TDM as they show a relatively small...
Autores principales: | , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8980857/ https://www.ncbi.nlm.nih.gov/pubmed/35392223 http://dx.doi.org/10.3389/fonc.2022.821807 |
_version_ | 1784681488129720320 |
---|---|
author | Verougstraete, Nick Stove, Veronique Verstraete, Alain G. Stove, Christophe P. |
author_facet | Verougstraete, Nick Stove, Veronique Verstraete, Alain G. Stove, Christophe P. |
author_sort | Verougstraete, Nick |
collection | PubMed |
description | Therapeutic drug monitoring (TDM) of tyrosine kinase inhibitors (TKIs) is not yet performed routinely in the standard care of oncology patients, although it offers a high potential to improve treatment outcome and minimize toxicity. TKIs are perfect candidates for TDM as they show a relatively small therapeutic window, a wide inter-patient variability in pharmacokinetics and a correlation between drug concentration and effect. Moreover, most of the available TKIs are susceptible to various drug-drug interactions and medication adherence can be checked by performing TDM. Plasma, obtained via traditional venous blood sampling, is the standard matrix for TDM of TKIs. However, the use of plasma poses some challenges related to sampling and stability. The use of dried blood microsamples can overcome these limitations. Collection of samples via finger-prick is minimally invasive and considered convenient and simple, enabling sampling by the patients themselves in their home-setting. The collection of small sample volumes is especially relevant for use in pediatric populations or in pharmacokinetic studies. Additionally, working with dried matrices improves compound stability, resulting in convenient and cost-effective transport and storage of the samples. In this review we focus on the different dried blood microsample-based methods that were used for the quantification of TKIs. Despite the many advantages associated with dried blood microsampling, quantitative analyses are also associated with some specific difficulties. Different methodological aspects of microsampling-based methods are discussed and applied to TDM of TKIs. We focus on sample preparation, analytics, internal standards, dilution of samples, external quality controls, dried blood spot specific validation parameters, stability and blood-to-plasma conversion methods. The various impacts of deviating hematocrit values on quantitative results are discussed in a separate section as this is a key issue and undoubtedly the most widely discussed issue in the analysis of dried blood microsamples. Lastly, the applicability and feasibility of performing TDM using microsamples in a real-life home-sampling context is discussed. |
format | Online Article Text |
id | pubmed-8980857 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | Frontiers Media S.A. |
record_format | MEDLINE/PubMed |
spelling | pubmed-89808572022-04-06 Therapeutic Drug Monitoring of Tyrosine Kinase Inhibitors Using Dried Blood Microsamples Verougstraete, Nick Stove, Veronique Verstraete, Alain G. Stove, Christophe P. Front Oncol Oncology Therapeutic drug monitoring (TDM) of tyrosine kinase inhibitors (TKIs) is not yet performed routinely in the standard care of oncology patients, although it offers a high potential to improve treatment outcome and minimize toxicity. TKIs are perfect candidates for TDM as they show a relatively small therapeutic window, a wide inter-patient variability in pharmacokinetics and a correlation between drug concentration and effect. Moreover, most of the available TKIs are susceptible to various drug-drug interactions and medication adherence can be checked by performing TDM. Plasma, obtained via traditional venous blood sampling, is the standard matrix for TDM of TKIs. However, the use of plasma poses some challenges related to sampling and stability. The use of dried blood microsamples can overcome these limitations. Collection of samples via finger-prick is minimally invasive and considered convenient and simple, enabling sampling by the patients themselves in their home-setting. The collection of small sample volumes is especially relevant for use in pediatric populations or in pharmacokinetic studies. Additionally, working with dried matrices improves compound stability, resulting in convenient and cost-effective transport and storage of the samples. In this review we focus on the different dried blood microsample-based methods that were used for the quantification of TKIs. Despite the many advantages associated with dried blood microsampling, quantitative analyses are also associated with some specific difficulties. Different methodological aspects of microsampling-based methods are discussed and applied to TDM of TKIs. We focus on sample preparation, analytics, internal standards, dilution of samples, external quality controls, dried blood spot specific validation parameters, stability and blood-to-plasma conversion methods. The various impacts of deviating hematocrit values on quantitative results are discussed in a separate section as this is a key issue and undoubtedly the most widely discussed issue in the analysis of dried blood microsamples. Lastly, the applicability and feasibility of performing TDM using microsamples in a real-life home-sampling context is discussed. Frontiers Media S.A. 2022-03-22 /pmc/articles/PMC8980857/ /pubmed/35392223 http://dx.doi.org/10.3389/fonc.2022.821807 Text en Copyright © 2022 Verougstraete, Stove, Verstraete and Stove https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms. |
spellingShingle | Oncology Verougstraete, Nick Stove, Veronique Verstraete, Alain G. Stove, Christophe P. Therapeutic Drug Monitoring of Tyrosine Kinase Inhibitors Using Dried Blood Microsamples |
title | Therapeutic Drug Monitoring of Tyrosine Kinase Inhibitors Using Dried Blood Microsamples |
title_full | Therapeutic Drug Monitoring of Tyrosine Kinase Inhibitors Using Dried Blood Microsamples |
title_fullStr | Therapeutic Drug Monitoring of Tyrosine Kinase Inhibitors Using Dried Blood Microsamples |
title_full_unstemmed | Therapeutic Drug Monitoring of Tyrosine Kinase Inhibitors Using Dried Blood Microsamples |
title_short | Therapeutic Drug Monitoring of Tyrosine Kinase Inhibitors Using Dried Blood Microsamples |
title_sort | therapeutic drug monitoring of tyrosine kinase inhibitors using dried blood microsamples |
topic | Oncology |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8980857/ https://www.ncbi.nlm.nih.gov/pubmed/35392223 http://dx.doi.org/10.3389/fonc.2022.821807 |
work_keys_str_mv | AT verougstraetenick therapeuticdrugmonitoringoftyrosinekinaseinhibitorsusingdriedbloodmicrosamples AT stoveveronique therapeuticdrugmonitoringoftyrosinekinaseinhibitorsusingdriedbloodmicrosamples AT verstraetealaing therapeuticdrugmonitoringoftyrosinekinaseinhibitorsusingdriedbloodmicrosamples AT stovechristophep therapeuticdrugmonitoringoftyrosinekinaseinhibitorsusingdriedbloodmicrosamples |